Liron Walsh

Liron Walsh currently serves as the Head of Development for In Vivo Programs at Intellia Therapeutics, Inc., since June 2021. Prior to this role, Liron was the VP of Clinical and Translational Nephrology at Goldfinch Biopharma, Inc. from June 2017 to June 2021, focusing on precision therapies for kidney disease. Liron also held the position of Medical Director at BioMarin Pharmaceutical Inc., overseeing rare disease programs, and worked as a Clinical Research Medical Director at Amgen, contributing to pivotal clinical trials. Earlier experience includes directing a hospitalist medicine program at Apogee Physicians, completing nephrology fellowship training at Mount Sinai School of Medicine, and conducting research at Beth Israel Medical Center. Liron holds an MD from the University of Toronto and a BS in Biology from York University.